RxDoctor Payments Data

Pavida Pachariyanon, MD

Advanced Heart Failure and Transplant Cardiology · Iowa City, IANPI 1558882670

Payments from drug & device makers

What this record shows

This record is dominated by travel and lodging: $7,832 of the $10,604 with a category attached, or 73.9%. Abbott accounts for 86.0% of it on its own, with 11 other manufacturers making up the rest. 2025 is the largest year on record at $5,482, more than ten times the $91 reported in 2020.

$10,604in general payments, 2019–2025

Across 97 payments — averaging $109.32 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Abbott$9K
  • Abiomed$637
  • Impulse Dynamics (USA) Inc.$208
  • Boehringer Ingelheim$132
  • Pfizer$130
  • AstraZeneca$111
  • plus $263 from 6 others

What the payments were for

  • Travel & lodging$7,83274%
  • Food & beverage$2,77226%

General payments by program year

20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

Too few advanced heart failure and transplant cardiology providers in Iowato place this figure against a meaningful peer group, so we don't.

Medicare billing

Part B allowed, 2024
$28,262
Medicare patients
107
Services billed
285

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin40$35,462
EntrestoSacubitril/Valsartan26$25,115
Bumetanide38$1,755
Potassium Chloride34$828
Spironolactone32$165
Losartan Potassium17$138
Metoprolol Succinate21$123
Warfarin Sodium12$119
Atorvastatin Calcium12$102
Isosorbide Mononitrate ErIsosorbide Mononitrate11$70
Furosemide23$59

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimJardiance$132$35,46240 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. There are too few advanced heart failure and transplant cardiology providers in Iowaon file to place this against a meaningful peer group, so we don't.

Other advanced heart failure and transplant cardiology in Iowa City

See the full list for Iowa

Where these figures come from

Is this you, or does something look wrong? →